Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ: REPL ) with a Neutral and raises the price target from $6 to $9.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.